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Background: Lung transplant recipients develop lung cancer more commonly than the general population.
The best treatment approach for these patients is unclear. The goal of this study is to evaluate treatment
outcomes in this population.
Methods: We used the Cleveland Clinic lung transplant database to identify patients diagnosed with lung
cancer at the time of or after lung transplant. Transplant and lung cancer-related data were retrospectively
reviewed.
Results: Among 847 patients underwent lung transplant between 2005 and 2013, 17 (2%) were diagnosed
with lung cancer and included. Median age was 61 (range, 48–70) years. Majority were stage I/II (n=11),
one had stage IIIA, five had stage IV. Non-small cell lung cancer (NSCLC) were more common than small
cell lung cancer (SCLC) (n=15 vs. 2). Curative treatment was performed as lobectomy in native lung (n=1),
and radiation in transplanted lung (n=2). Chemotherapy was given in 10 patients, primarily carboplatinbased doublets with docetaxel, pemetrexed, or etoposide. Six of these received palliative chemotherapy for
either metastases at diagnosis (n=3) or recurrence after early stage disease (n=3). Except for one patient with
complete response, all others had progressive disease following palliative chemotherapy. Overall, patients
who received chemotherapy had a median survival of 7.5 months from the initiation of chemotherapy, but
30% developed grade 5 sepsis. Median survival for stage I–IIIA and stage IV were 23.2 and 2.5 months
respectively.
Conclusions: Lung cancer in lung transplant recipients carries various clinical courses. Patients with
metastatic disease have substantial toxicities from chemotherapy and poor survival. Early stage patients
should be offered treatment with modified dosages to decrease the risk of severe toxicities.
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Introduction
Lung transplant is utilized as a last resort and can be an
effective treatment for patients with end stage lung disease.
The incidence of lung cancer in lung transplant recipients is
higher than that in general population (1-5). Contributing
factors include significant smoking history, which is

commonly noted in patients with lung cancer. Chronic
immunosuppressed status after transplant is also thought to
be a contributing risk factor (6). As the number of patients
undergoing lung transplantation is increasing, more
bronchogenic carcinomas are being detected after lung
transplantation. There is a paucity of literature regarding
treatment outcomes among lung transplant survivors who
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Table 1 Patient and transplant characteristics
Characteristic

N [%]

Gender
Male
Female
Age at transplant, median [range]

13 [76]
4 [24]
61 [48–70]

Smoking history
Never

1 [6]

Former

15 [88]

Current

1 [6]

Transplant KPS €
50–60

3 [30]

70–80

7 [70]

Post-transplant KPS ¥
40–60

8 [53]

70–80

7 [47]

Underlying lung disorder
ILD +/− COPD $

13 [76]

COPD

3 [18]

Chronic berylliosis

1 [6]

Lung transplant
Unilateral

9 [53]

Bilateral

8 [47]

Immunosuppression
MMF

10 [59]

AZT

2 [12]

MMF + AZT

3 [18]

Neither

2 [12]

Pulse steroid 1st year
Yes

6 [35]

No

11 [65]

Antibody-mediated rejection
Yes

3 [18]

No

14 [82]

Acute cellular rejection episodes
0

4 [24]

1

5 [29]

2

4 [24]

>2

4 [24]

€, Karnofsky Performance Scale (KPS). Data missing on seven
patients at the time of transplant; ¥, Karnofsky Performance
Scale. Data missing on two patients at second post-op visit
after transplant; $, ILD, interstitial lung disease. Includes usual
interstitial pneumonia (UIP), non-specific interstitial pneumonia
(NSIP), with or without COPD. COPD, chronic obstructive
pulmonary disease; MMF, mycophenolic acid; AZT, azathioprine.
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are diagnosed with lung cancer. As a result, there is a lack
of consensus on the best treatment strategy for this rare
population of patients.
We have conducted a retrospective review on a large
cohort of lung transplant patients to identify the incidence
and treatment outcomes after a lung cancer diagnosis
among lung transplant recipients.
Methods
The Cleveland Clinic lung transplantation database was used
to identify patients with lung cancer diagnosed at the time
of or after lung transplant. Clinical information including
demographics, underlying lung disease, type of transplant,
immunosuppressive regimen, lung cancer pathologies,
cancer-related treatment, response, and toxicities were
retrospectively reviewed and collected. Survival time was
calculated from the diagnosis of lung cancer to expiration or
last date patient known to be alive. In patients who received
chemotherapy for lung cancer, survival was also calculated
from the initiation of chemotherapy to expiration or last
known alive. The study was approved by the Institutional
Review Board of Cleveland Clinic Foundation.
Results
Between 2005 and 2013, 847 patients underwent a single
or bilateral lung transplant at Cleveland Clinic Foundation.
Of these patients, 17 (2%) were diagnosed with lung cancer
subsequent to the transplant and were included in the study.
Patient demographics and transplant characteristics are
shown in Table 1. Most of the patients were male (76%) and
former smokers (88%). The median age at lung transplant
was 61 (range, 48–70) years. The majority of patients had
lung transplantation for interstitial lung disease with or
without chronic obstructive pulmonary disease (COPD)
(76%). Nearly half of the patients underwent bilateral lung
transplant (47%).
Tumor location and histology
Eight cancers were detected in the explanted lung at the
time of lung transplantation (47%), five were diagnosed in
the remaining native lung (29%), and three cancers were
later diagnosed in the transplanted (donor’s) lung (18%).
One patient had lung cancer present as distant metastasis
without an identified primary lesion (6%). Lung cancers
detected in the native and transplanted lung were diagnosed
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Table 2 Lung cancer characteristics
Characteristic

Table 2 (continued)
N [%]

Involved lung

Characteristic

N [%]

ECOG at diagnosis of cancer €

Explanted

8 [47]

0–1

9 [69]

Native remaining

5 [29]

2–3

4 [31]

Transplanted

3 [18]

Unknown $

CXT

8 [50]

RT

2 [13]

cancer (patients with cancer in remaining

CXT + RT

2 [13]

native or transplanted lung) ￠ , median

Neither

Time (months) between transplant and lung

1 [6]

Initial non-surgical cancer treatment

26.7 (7.9–64.8)

(range)

4 [25]
st

Best response to 1 line CXT ¥

T-stage

CR

2 [25]

T1–2

11 [65]

PR

0 [0]

T3–4

4 [24]

SD

2 [25]

Tx

2 [12]

PD

4 [50]

Nodal involvement

Highest grade toxicity to 1st line CXT

No

8 [47]

1–2

8 [80]

Yes

7 [41]

3–4

0 [0]

Unknown

2 [12]

5

2 [20]

Stage at diagnosis

$, Distant metastatic disease at diagnosis without known

I

6 [35]

lung lesion; ￠ , excluding patients with cancer in explanted

II

5 [29]

lung; €, Eastern Cooperative Oncology Group Performance

III

1 [6]

Status. Data missing on four patients at first oncology visit;

IV

5 [29]

¥, data missing on two patients. NSCLC, non-small cell lung
cancer; CXT, chemotherapy; RT, radiation therapy; CR, com-

Histology
Adenocarcinoma

6 [35]

Squamous cell carcinoma

5 [29]

Mixed

1 [6]

Adenocarcinoma in situ

2 [12]

Pleomorphic NSCLC

1 [6]

Small cell

2 [12]

Table 2 (continued)

at a median of 26.7 months (range, 7.9 months–5.4 years)
after the transplant. The majority of patients (n=11) had
early stage disease (stage I/II) (64%), one patient had locally
advanced stage IIIA (6%) and five (29%) were stage IV
disease at the time of diagnosis. Most patients with early
stage disease were detected in the explanted lung at the
time of transplant (n=8/11), few in the transplanted lung
(n=2/11), and only one patient in the native lung after a
single transplant.
Non-small cell lung cancer (NSCLC), was more
common (n=15, 88%) than small cell lung cancer (SCLC)

© Translational lung cancer research. All rights reserved.

plete response; PR, partial response; SD, stable disease; PD,
progression of disease.

(n=2, 12%). NSCLC histology included squamous cell
carcinoma (n=6), adenocarcinoma (n=6), adenocarcinoma
in situ (n=2), and pleomorphic NSCLC (n=1). Lung cancer
characteristics and treatment outcomes are summarized in
Tables 2 and 3.
Treatment with a curative intent
Overall 12 out of 17 patients had potential curable disease
(stage I–IIIA) and except for one patient, who did not
receive adjuvant chemotherapy for stage II disease, all
others were treated with stage-appropriate treatment.
Among 12 patients with potential curable disease, eight
patients had cancer in explanted lung and did not receive
adjuvant therapy if diagnosed with stage I disease (5/8
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Table 3 Disease and treatment characteristics and outcome
No.

Site of disease

Oncologic treatment modality

1

Stage Histology
I

Adeno

Ex-lung

No treatment

Chemo regimen

No. of chemotherapy cycles Dose of chemotherapy

2

I

Squamous

Ex-lung

CXT for mets, palliative RT

3

I

Adeno

Ex-lung

No treatment

–

–

–

4

I

Adeno

Ex-lung

No treatment

–

–

–

5

I

SCLC

Tx-lung

RT, CXT definitive Tx

Carboplatin/etoposide

4

6

I

Adeno

Ex-lung

CXT for mets in Tx-lung

1st line: carboplatin/pemetrexed

4

–
Carboplatin/docetaxel

Best response

Dose of radiation

Survival (months)

–

–

18.8 (alive)

PD

25 Gy/5 fx

19.4

–

–

23.3 ¥

–

–

8.9 (alive)

Unknown

CR

50 Gy/5 fx

14.3 (alive)

Carboplatin AUC 5/pemetrexed 500 mg/m2 (C1),

CR

–

27.9

–

24

–

–

29.20 €

SD

–

12.9 ₠

PD

50 Gy/5 fx

3.2

–

13.3

Unknown

9.4

–
3

–
Unknown

carboplatin AUC 4/pemetrexed 400 mg/m2 (C2–C4)
Pemetrexed maintenance
7

II

Squamous

Ex-lung, LN

st

1 line: carboplatin/docetaxel

CXT adjuvant

3

500 mg/m2

SD

3

Carboplatin AUC 6/docetaxel 75 mg/m2 (C1),

SD

2

carboplatin AUC 5/docetaxel 75 mg/m (C2),
carboplatin AUC 5/docetaxel 55 mg/m2 (C3)
nd

2 line: erlotinib (started when liver

–

150 mg/daily

PR

mets developed)
8
9

II
II

Adeno in situ
Squamous

Ex-lung
Ex-lung, LN

No treatment

–
st

CXT adjuvant

1 line: carboplatin/docetaxel

–
3

–
2

Carboplatin AUC 5/docetaxel 37.5 mg/m (C1),
carboplatin AUC 5/docetaxel 55 mg/m2 (C2),
carboplatin AUC 5/docetaxel 75 mg/m2 (C3)

10
11
12

II
II
IIIA

Squamous
Adeno in situ

Tx-lung
Na-lung, LN

Adeno

Pleomorphic NSCLC LN, bone

IV

Adeno

Na-lung, LN, bone

Carboplatin AUC 6/docetaxel 75 mg/m2

st

Unknown

1 line: carboplatin/pemetrexed

2

Unknown

Unknown

2nd line: erlotinib

–

Unknown

PD

Na-lung, LN, malignant pleural effusion No treatment

IV
IV

Unknown

1

CXT for mets later
Na-lung, LN

13

1

Carboplatin/docetaxel

Surgery for localized disease,

Squamous

14
15

RT, CXT definitive Tx

2nd line: carboplatin/etoposide

RT

–

Palliative RT
CXT for mets

–

–

–

–

–

–

–

–

2.7

–

–

–

–

20 Gy/5 fx

1.3

PD

–

4.7

Carboplatin/pemetrexed

3

2

Carboplatin AUC 5/pemetrexed 500 mg/m (C1),
carboplatin AUC 5/pemetrexed 450 mg/m2 (C2),
carboplatin AUC 5/pemetrexed 400 mg/m2 (C3)

16

IV

SCLC

Tx-lung, liver, bone

CXT for mets

Cisplatin/etoposide

17

IV

Squamous

Na-lung, LN, liver, bone

CXT for mets

Unclear agents

6

Unknown

PD

–

9.8

Unknown

Unknown

PD

–

2.1

¥, Patient died secondary to lung transplant rejection; €, sudden death of unknown cause; ₠, patient died secondary to sepsis. Adeno, adenocarcinoma; squamous, squamous cell carcinoma; SCLC, small cell lung cancer; adeno in situ, adenocarcinoma in situ; NSCLC, non-small cell
lung cancer; Ex-lung, explanted lung; Tx-lung, transplanted lung; LN, lymph node; Na-lung, native lung remaining; CXT, chemotherapy; mets, metastases; RT, radiation therapy; AUC, area under the curve; C1/2/3/4, cycle 1/2/3/4; PD, progression of disease; CR, complete response; SD,
stable disease; PR, partial response; fx, fractions.
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explanted lung cancers were stage I). Two of these patients
with stage I disease in explanted lung later developed
relapsed disease in their transplanted lung (40%) and at that
point, both patients were treated with chemotherapy. One
patient also received additional palliative radiation.
Curative oncologic treatment beyond removal of
explanted lung in stage I disease was offered based on stage
and site of disease, and included lobectomy, radiation,
sequential radiation followed by chemotherapy, and
adjuvant chemotherapy. Lobectomy was performed in a
patient with T2N1M0, stage II lung cancer in remaining
native lung; however, this patient developed metastases
5 months later, and died 7 months after chemotherapy
was initiated. Sequential radiation (50 Gy in 5 fractions)
followed by chemotherapy was delivered to two patients
with cancer in transplanted lung (one with stage I small cell
lung cancer, and the other with stage II NSCLC disease).
Adjuvant chemotherapy was administered in 2 out of 3
patients with stage II disease in explanted lung.

Du et al. Lung cancer outcome in lung transplant recipients

response 3 months after initiation of chemotherapy.
Among patients with measurable disease who were given
chemotherapy with curative intent (n=2), one had a
complete response after sequential radiation followed by
chemotherapy for SCLC, and the other had progression of
disease as best response after receiving sequential radiation
and chemotherapy for stage II squamous cell disease in
transplanted lung.
Treatment outcome (Table 4)

Chemotherapy was given in 10/17 (59%) all patients,
primarily carboplatin-based doublets (n=8), paired with
docetaxel, pemetrexed, or etoposide.
Upfront chemotherapy in the form of adjuvant treatment
or combined with radiation was offered in 40% of all
chemotherapy-treated patients (4/10) and the remaining
60% were treated with a palliative intent (6/10), half
of whom were initially stage I or II at diagnosis. The
remaining seven patients (41%) who were not treated with
chemotherapy during their cancer treatment included four
patients with early stage cancer in explanted lung (three
with T1N0 stage I and one with T3N0 stage II), one patient
with stage IIIA disease in remaining native lung treated with
radiation alone, and two patients with stage IV metastatic
disease.
Among patients with early stage disease (stage I–II,
n=11), a total of seven patients received chemotherapy +/−
radiation for either nodal involvement in the explanted
lymph nodes (n=2), disease in the transplanted lung
after bilateral transplant (n=2), or later, when metastases
developed (n=3).
Among those patients who received chemotherapy
with a palliative intent for metastatic disease (n=6), best
radiographic response was progressive disease during
treatment in three (50%) and not evaluable in two other
patients (33%), however, one patient had a complete

Median survival from the diagnosis of lung cancer was
better in patients who had cancer in the explanted lung than
in those who developed cancer at a later date in the native
or transplanted lungs: 24 months [confidence interval (CI),
12.9–29 months] vs. 4.8 months (CI, 1.3–13.3 months).
Unsurprisingly, median survival is also more favorable in
stage I–IIIA (23.2 months; CI, 9.4–27.8 months) compared
to stage IV disease (2.5 months; CI, 1.3–9.7 months).
Median survival of early stage patients (stage I–II) who
received treatment was 14.3 months (range, 3.2–27.9 months).
Two died of grade 5 neutropenia and sepsis at 3 and 13
months after the diagnosis of cancer. Also of note, two
patients had a complete response to first-line chemotherapy.
One was still alive 14.3 months after cancer diagnosis
(when data was collected). The other patient unfortunately
developed lung rejection at which point chemotherapy had
to be stopped, with a survival time of 27.9 months after the
diagnosis of lung cancer, 10 months after the initiation of
chemotherapy. Early stage patients without treatment (n=4)
had a median survival of 21 months (range, 8.9–29.2 months),
two of whom died of causes unrelated to lung cancer (one due
to lung rejection, and one due to sudden death of unknown
cause).
Median survival of patients with stage IV metastatic
disease at diagnosis was 2.7 months (range, 1.3–9.8 months)
and those who received chemotherapy had slightly longer
survivals (2.1–9.8 months) compared to those who did
not receive chemotherapy (1.3 and 2.7 months). Of those
patients who received chemotherapy, best response was
documented as progression of disease in two patients
(survival 4.7, and 9.8 months from diagnosis), and early
death secondary to sepsis after first cycle of chemotherapy
in third patient (survival 2.1 months). Due to small number
of patients (n=5), no direct statistical comparison was
performed among patients treated with chemotherapy vs.
best supportive care only.
Patients who later developed metastatic disease, however,
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Table 4 Survival outcomes
Outcome

No. death [%]

Median survival months (95% CI)

Overall survival
Survival from transplant

14 [82]

23.6 (19.4–58.7)

Survival from lung cancer diagnosis

14 [82]

13.3 (2.8–24.0)

8 [89]

7.5 (0.3–20.6)

9 [100]

20.0 (12.9–70.0)

Survival from initiation of CXT
Survival from transplant
Unilateral
Bilateral

5 [62]

24.0 (NA)

Explanted lung

6 [75]

24.0 (12.9–29.0)

Native or transplanted lung

7 [88]

41.1 (17.7–77.6)

Survival from lung cancer diagnosis
Unilateral

9 [100]

9.7 (2.0–19.7)

Bilateral

5 [62]

23.6 (1.3–29.0)

Explanted lung

6 [75]

21.3 (8.9–29.2)

Native or transplanted lung

7 [87]

7.0 (2.1–14.3)

I-III

9 [75]

23.2 (9.4–27.8)

IV

5 [100]

2.5 (1.3–9.7)

0–1

7 [78]

13.3 (2.0–27.8)

2–3

4 [100]

12.7 (1.3–19.7)

Stage-specific survival (ECOG)

Performance-specific survival (ECOG) ￠

￠ , Eastern Cooperative Oncology Group Performance Status at the time of cancer diagnosis. CXT, chemotherapy; CI, confidence
interval; NA, not available.

had a mixed response subsequent to chemotherapy. Three
patients with early stage I–II who later developed metastasis
were treated with chemotherapy. One patient with NSCLC
had a complete response to therapy, but later discontinued
continuous maintenance treatment due to transplant
rejection. This patient lived to 10 months after initiation of
chemotherapy (27.9 months since initial diagnosis of lung
cancer). Another patient developed pancytopenia after two
cycles of chemotherapy, did not have a formal response
evaluation, and was switched to erlotinib. Unfortunately,
this patient had progression of disease through erlotinib
and lived for 5.5 months since starting systemic therapy
(6.7 months since diagnosis of metastatic disease, 13.3 months
from diagnosis of early stage lung cancer). The third patient
had progression of disease as best response to chemotherapy
with a poor survival since diagnosis of metastatic disease and
initiation of chemotherapy (5.7 and 2.6 months, respectively;
19.4 months overall survival since diagnosis of cancer).
The initial gap between diagnosis of metastatic disease and

initiation of systemic treatment in this patient was due to
confirmation and palliative radiation to soft tissue.
In general, patients who received chemotherapy had a
median survival of 7.5 months (95% CI, 0.3–20.6 months)
from the initiation of chemotherapy. Anemia (30%) and
fatigue (30%) were the most common toxicities, while
sepsis was most severe and the cause of death in 30% of
chemotherapy-treated patients (n=3/10).
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Discussion
The reported rate of developing lung cancer after lung
transplantation is 1.0–4.1% (1,3,4,7), much higher than
that of 0.2% in the general population (5). The incidence
of lung cancer in our cohort was 2%, which is in line with
prior studies. Review of available literature shows lung
cancer to be more commonly detected after single-lung
transplantation compared to bilateral lung transplant. The
incidence of developing lung cancer in patients with single
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lung transplant is 6.9–9.8%, whereas that after bilateral
lung transplant it is 0–1.8% (4,8). Most of the bronchogenic
carcinomas were found in the native lung after single lung
transplant (1,3,4,7-10). In contrast, in our study, only
5 out of 17 cases developed cancer in native lung after
single transplant; 3 of whom were detected at an advanced
stage with metastases to bone (n=3) and liver (n=2). In
comparison, our study identified a significant number of
cancers detected in explanted lungs (n=8), all associated
with early stage disease with a better prognosis [median
survival 21 months (range, 8.9–29.2 months)] compared to
cancer in the native or transplanted lung [median survival
7.2 months (range, 2.1–14.3 months)]. The incidence of
lung cancer detection in explanted lungs is 0.9% in our
study population, which is again, in concordance with
previous studies reporting an incidence of 0.8–2.0% of lung
cancer found in explanted lungs (1,11).
Literature regarding the treatment of lung cancer
in lung transplant recipients is scant. Treatment option
for this group of patient is often limited given their
immunosuppressive status and comorbidities. In our study,
patients with advanced stage disease generally had poor
survival regardless of chemotherapy. The longest surviving
patient with stage IV upon diagnosis (survival 9.8 months
from diagnosis) had small cell lung cancer and received
chemotherapy with carboplatin/etoposide. The other four
patients with metastatic disease at diagnosis had NSCLC
with survival ranging between 1.3 to 4.7 months.
Patients who later developed metastatic disease, however,
had a mixed response subsequent to chemotherapy. Three
patients with stage I–II who later developed metastasis were
treated with systemic therapy with best response measured
as complete response in one, progression of disease in
another, and not evaluable in the third case. The longest
surviving patient was the one with complete response
(10 months since initiation of chemotherapy) who eventually
succumbed to transplant rejection rather than malignancy.
Overall, it appears that response to chemotherapy in the
palliative setting is very low in this population, although
occasional cases of complete response can be found. The
more challenging aspect of treatment, however, remains the
high toxicity rate with hematologic grade 4–5 events being
common. Patients who were treated with chemotherapy
numerically had a longer survival than those who were
not treated, but it is difficult to control for the possible
difference in comorbidities and performance in this
retrospective review. In addition, it appears that patients
who were initially diagnosed with early stage disease may

have a better response to palliative chemotherapy when
they develop metastasis compared to those with stage IV
at diagnosis, however, risk of hematologic toxicities remain
high in this population as well.
Patients with early stage disease detected in explanted
lungs without nodal involvement had a reasonable survival
without immediate additional treatment. Among five
patients with stage I lung cancer discovered in explanted
lung, two were alive at the time of data capture (9 and
19 months since diagnosis of cancer), and remaining
patients had lived a median survival of 23.3 months (range,
19.4–27.9 months).
In addition, chemotherapy could be offered to those
early stage patients with nodal involvement, those with
disease in transplanted lung or remaining native lung
after unilateral lung transplant, or patients with relapsed
disease. Chemotherapy in this group results in higher
rates of response and longer survival compared to those
patients receiving therapy for stage IV disease. However,
median survival in this group is numerically worse than
those with stage I lung cancer in explanted lung, who did
not receive chemotherapy. This difference to some extent
reflects biologic and stage impact of nodal involvement in
chemotherapy-treated group or comorbidities associated
with cancer in remaining native or transplanted lung as
compared to unexpected discovery of cancer in explanted
lung without nodal involvement. It is also possible that
some of the survival differences could be attributed to
adverse events from chemotherapy, and particularly sepsis
secondary to profound bone marrow suppression in this
already immune-compromised population.
In summary, the possible survival advantages of
chemotherapy must be weighed carefully against
serious adverse events. Patients with metastatic disease
had a numerically longer survival when treated with
chemotherapy, and there have been cases of complete
response in our cohort of chemotherapy-treated
patients. But chemotherapy-associated toxicities can
also be detrimental in this group of patients, as 30% of
chemotherapy-treated patients died of grade 5 sepsis.
Therefore modified regimens with careful dose reduction
along with bacterial and viral prophylaxis should be
considered when treating this group of patients in order to
decrease the risk of severe toxicities.
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transplantation carries various clinical courses. Patients
with metastasis have poor survival and significant toxicities
from chemotherapy, but variability in outcome still remains.
Early stage patients and those with lung cancer in explanted
lungs should be considered for treatment with a curative
intent, but modified and dose-reduced regimens along with
prophylactic antibiotics are highly encouraged to decrease
the chance of severe adverse events, including profound
neutropenia and sepsis.
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